<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275260</url>
  </required_header>
  <id_info>
    <org_study_id>EP025</org_study_id>
    <nct_id>NCT02275260</nct_id>
  </id_info>
  <brief_title>Reduction of AF Ablation Induced Thrombo-Embolic Incidence Pilot Study</brief_title>
  <official_title>Reduction of AF Ablation Induced Thrombo-Embolic Incidence Pilot Study (REDUCE-TE Pilot)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotronik SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The REDUCE-TE Pilot study is an international, multicenter, prospective, single arm study to
      compare the AlCath Flux eXtra Gold ablation catheter regarding the prevention of new
      subclinical cerebral thromboembolic lesions after Pulmonary Vein Isolation to historical data
      from the literature.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Required number of endpoints will be obtained with sample size lower as initially planned
  </why_stopped>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">May 2, 2017</completion_date>
  <primary_completion_date type="Actual">February 8, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thromboembolic lesions</measure>
    <time_frame>1-3 days</time_frame>
    <description>The occurrence of one or more new subclinical cerebral thromboembolic lesions after Pulmonary Vein Isolation assessed by Diffusion-Weighted MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive status</measure>
    <time_frame>Baseline, 1-3 days and 3 months</time_frame>
    <description>To assess the impact of PVI on the patient's neurocognitive status measured by a testing battery including the STATE questionnaire, d2 test of attention, visual part of the visual and verbal memory test (VVM2) and Montreal Cognitive Assessment (MOCA) subtest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-procedural serious adverse events</measure>
    <time_frame>Within 24 hours after ablation</time_frame>
    <description>Any serious adverse event occurring during the ablation procedure and within 24 hours from completion of the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedural clinical TE events</measure>
    <time_frame>3 months period</time_frame>
    <description>Composite endpoint: Occurrence of Transient Ischemic Attack and/or Ischemic Stroke and/or Systemic Embolism during the three months post-ablation period (excluding peri-procedural events)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acute procedural success rate</measure>
    <time_frame>During ablation</time_frame>
    <description>Acute procedural success of Pulmonary Vein Isolation, defined as electrical isolation of all Pulmonary Veins (entrance block)</description>
  </other_outcome>
  <other_outcome>
    <measure>Success of Pulmonary Vein Isolation</measure>
    <time_frame>3 months</time_frame>
    <description>Three months ablation success, defined as freedom from symptomatic AF recurrences off antiarrhythmic drug therapy assessed to three-month follow-up</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients undergo cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), Transesophageal (or Intracardial) Echocardiography and paperbased neurocognitive testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cerebral Diffusion-Weighted Magnetic Resonance Imaging</intervention_name>
    <description>Patients undergo a cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI)</description>
    <arm_group_label>All patients</arm_group_label>
    <other_name>1.5-3 T machine capable of Diffusion-Weighted MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transesophageal Echocardiography</intervention_name>
    <description>Patients undergo a Transesophageal Echocardiography prior to the ablation itself</description>
    <arm_group_label>All patients</arm_group_label>
    <other_name>Any Transesophageal Echocardiography machine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Paperbased neurocognitive testing</intervention_name>
    <description>To assess the impact of PVI on the patient's neurocognitive status</description>
    <arm_group_label>All patients</arm_group_label>
    <other_name>STATE questionnaire, d2 test, visual VVM2, MOCA subtest</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Electrocardiographically documented, symptomatic paroxysmal AF.

          -  Patients with indication for left atrial ablation of AF according to ESC guidelines
             for the management of atrial fibrillation.

          -  Anticoagulation according to clinical routine using coumarin derivates with target INR
             between 2.0 and 3.0 at least 3 weeks prior to the scheduled ablation procedure or
             novel oral anticoagulants (NOACs).

          -  Geographically stable for the duration of the study.

          -  Willingness and ability to perform written informed consent

        Exclusion Criteria:

          -  Long standing persistent or persistent AF

          -  CHA2DS2-VASc score ≥ 5

          -  Prior ischemic stroke or Transient Ischemic Attack

          -  Previous Pulmonary Vein ablation

          -  Contraindication for anticoagulation therapy

          -  Contraindication for Diffusion-Weighted MRI

          -  Claustrophobia

          -  Contraindication for transesophageal echocardiography (TEE) or intracardiac
             echocardiography (ICE, if TEE not possible)

          -  Implanted cardiovascular device, including but not limited to an atrial or ventricular
             pacemaker or defibrillator leads, artificial valves, stents, septal or LAA occluders

          -  Acute coronary syndrome &lt; 3 months prior to scheduled ablation

          -  Moderate to severe valvular heart disease

          -  LA size &gt; 55 mm (confirming echo at maximum 3 months old)

          -  Patients with non-controlled heart failure or patients with current and recent (&lt; 1
             month prior to ablation) heart failure

          -  Ejection fraction &lt; 35% (confirming echo at maximum 3 months old)

          -  Conditions that prevent patient's participation in neurocognitive assessment (at
             physician's discretion)

          -  Female patients who are pregnant or breast feeding or plan a pregnancy during the
             course of the study

          -  Any limitation to contractual capability

          -  Simultaneous participation in another study

          -  Age &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dipen Shah, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpitaux Universitaires de Genève, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Schmidt, PD Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Cardioangiologisches Centrum Bethanien, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ceske Budejovice Hospital</name>
      <address>
        <city>Budejovice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine (IKEM)</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardioangologisches Centrum Bethanien (CCB)</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München des Freistaates Bayern</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Osypka Herzzentrum München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Medical University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG - Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>Akca F, Zima E, Végh EM, Széplaki G, Skopál J, Hubay M, Lendvai Z, Merkely B, Szili-Torok T. Radiofrequency ablation at low irrigation flow rates using a novel 12-hole gold open-irrigation catheter. Pacing Clin Electrophysiol. 2013 Nov;36(11):1373-81. doi: 10.1111/pace.12215. Epub 2013 Jul 22.</citation>
    <PMID>23875670</PMID>
  </reference>
  <reference>
    <citation>Balázs T, Laczkó R, Bognár E, Akman S, Nagy P, Zima E, Dobránszky J, Szili-Török T. Ablation time efficiency and lesion volume - in vitro comparison of 4 mm, non irrigated, gold- and platinum-iridium-tip radiofrequency ablation catheters. J Interv Card Electrophysiol. 2013 Jan;36(1):13-8; discussion 18. doi: 10.1007/s10840-012-9743-9. Epub 2012 Oct 26.</citation>
    <PMID>23100094</PMID>
  </reference>
  <reference>
    <citation>Linhart M, Liberman I, Schrickel JW, Mittmann-Braun EL, Andrié R, Stöckigt F, Kreuz J, Nickenig G, Lickfett LM. Superiority of gold versus platinum irrigated tip catheter ablation of the pulmonary veins and the cavotricuspid isthmus: a randomized study comparing tip temperatures and cooling flow requirements. J Cardiovasc Electrophysiol. 2012 Jul;23(7):717-21. doi: 10.1111/j.1540-8167.2011.02267.x. Epub 2012 Mar 19.</citation>
    <PMID>22429859</PMID>
  </reference>
  <reference>
    <citation>Lewalter T, Weiss C, Spencker S, Jung W, Haverkamp W, Willems S, Deneke T, Kautzner J, Wiedemann M, Siebels J, Pitschner HF, Hoffmann E, Hindricks G, Zabel M, Vester E, Schwacke H, Mittmann-Braun E, Lickfett L, Hoffmeister S, Proff J, Mewis C, Bauer W; AURUM 8 Study Investigators. Gold vs. platinum-iridium tip catheter for cavotricuspid isthmus ablation: the AURUM 8 study. Europace. 2011 Jan;13(1):102-8. doi: 10.1093/europace/euq339. Epub 2010 Sep 28.</citation>
    <PMID>20876601</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

